Related Experiment Video

Updated: May 7, 2026

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

DiaPep277® and immune intervention for treatment of type 1 diabetes

Nanette C Schloot1, Irun R Cohen

  • 1Institute for Clinical Diabetology, German Diabetes Center, Leibniz-Center for Diabetes Research, Heinrich-Heine University, Düsseldorf, Germany.

Clinical Immunology (Orlando, Fla.)
|October 5, 2013
PubMed

Insights

Type 1 diabetes immune intervention trials show partial success in preserving C-peptide in newly diagnosed patients. However, no immune-based therapy has yet cured type 1 diabetes or gained drug approval.

Area of Science:

  • Immunology
  • Endocrinology
  • Clinical Trials

Background:

  • Type 1 diabetes is an autoimmune disease causing beta-cell destruction.
  • Current research aims to halt progression, reduce risk, and prevent onset.
  • Existing secondary prevention trials have been unsuccessful.

Purpose of the Study:

  • To review immune intervention trials for type 1 diabetes.
  • To summarize current knowledge on DiaPep277® peptide as an immune intervention.

Main Methods:

  • Review of clinical trials targeting T-cells and inflammation.
  • Analysis of antigen-specific immune modulation and stem cell approaches.
  • Evaluation of DiaPep277® peptide's role in immune intervention.

Main Results:

  • Trials in newly diagnosed patients show partial success in C-peptide preservation.
  • No immune-based regimen has cured type 1 diabetes post-onset.
  • No immune intervention has stabilized C-peptide decline to drug approval status.

Conclusions:

  • Immune intervention strategies show promise but require further development.
  • DiaPep277® peptide represents a potential avenue for immune intervention in type 1 diabetes.
  • Achieving a cure or stable C-peptide preservation remains an unmet clinical need.
Keywords:
C-peptideImmunotherapyT cellsType 1 diabetes

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...